SCHEMBL2473003

SCHEMBL2473003

O=c1[nH]nnc2nc[nH]c12

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.64
PNP P00491 1/20 0.48
PDPK1 O15530 1/20 0.44
GRIA1 P42261 1/20 0.41
GRIA2 P42262 1/20 0.41
GRIA3 P42263 1/20 0.41
GRIA4 P48058 1/20 0.41
GDA Q9Y2T3 2/20 0.40
ACHE P22303 1/20 0.39
XDH P47989 3/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38
ADORA2A P29274 1/20 0.38
SLC6A4 P31645 1/20 0.38
ADRA1A P35348 1/20 0.38
RAB9A P51151 1/20 0.38
BLM P54132 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
DPP4 P27487 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1230978 0.85 ALDH1A1 (0.61) ALDH1A1PNPPDPK1GRIA1GRIA2
Hypoxanthine SCHEMBL25381 0.79 ALDH1A1 (1.00) ALDH1A1PNPPDPK1GRIA1GRIA2
Hypoxanthine SCHEMBL30096461 0.79 ALDH1A1 (1.00) ALDH1A1PNPPDPK1GRIA1GRIA2
Hypoxanthine SCHEMBL7037918 0.79 ALDH1A1 (1.00) ALDH1A1PNPPDPK1GRIA1GRIA2
Hypoxanthine SCHEMBL28774651 0.77 ALDH1A1 (0.95) ALDH1A1PNPPDPK1GRIA1GRIA2
Hypoxanthine SCHEMBL122843 0.77 ALDH1A1 (0.95) ALDH1A1PNPPDPK1GRIA1GRIA2
Hypoxanthine SCHEMBL560392 0.77 ALDH1A1 (0.95) ALDH1A1PNPPDPK1GRIA1GRIA2
Hypoxanthine SCHEMBL30703487 0.77 ALDH1A1 (0.95) ALDH1A1PNPPDPK1GRIA1GRIA2
Hypoxanthine SCHEMBL2639254 0.77 ALDH1A1 (0.95) ALDH1A1PNPPDPK1GRIA1GRIA2
Hypoxanthine SCHEMBL7168422 0.77 ALDH1A1 (0.95) ALDH1A1PNPPDPK1GRIA1GRIA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078158-A1 COMPOSITIONS COMPRISING CXCL10-DERIVED PEPTIDES AND METHODS OF USE THEREOF UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2026-03-19 US claimed
CN-119269680-A Metabolic marker for diagnosing abdominal aortic aneurysm and application thereof 首都医科大学附属北京友谊医院 2025-01-07 CN claimed
WO-2024050567-A2 COMPOSITIONS COMPRISING CXCL10-DERIVED PEPTIDES AND METHODS OF USE THEREOF UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2024-03-07 WO claimed
CN-111971291-A Cyclic dinucleotide compounds containing 2-aza-hypoxanthine or 6H-pyrazolo [1,5-D ] [1,2,4] triazin-7-one as STING agonists 勃林格殷格翰国际有限公司 2020-11-20 CN claimed
WO-2019172268-A1 PLANT DISEASE CONTROL AGENT 国立大学法人静岡大学 2019-09-12 WO claimed
US-8518859-B2 Method for increasing yield of staple food crop NATIONAL UNIVERSITY CORPORATION SHIZUOKA UNIVERSITY (JP) 2013-08-27 US claimed
US-20120122690-A1 Method For Increasing Yield Of Staple Food Crop NATIONAL UNIVERSITY CORPORATION SHIZUOKA (JP) 2012-05-17 US claimed
JP-11278977-A None JP disclosed
EP-4735593-A1 POLYNUCLEOTIDE SYNTHESIS METHOD, KIT AND SYSTEM Oxford Nanopore Technologies PLC (GB) 2026-05-06 EP disclosed
US-20260078158-A1 COMPOSITIONS COMPRISING CXCL10-DERIVED PEPTIDES AND METHODS OF USE THEREOF UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2026-03-19 US disclosed
US-12527801-B2 Cell activator of animal cell VITAMIN C60 BIORESEARCH CORPORATION (JP) 2026-01-20 US disclosed
US-20250382344-A1 Soluble GLP1/GIP/NPY2 Receptor Triple Agonists BOEHRINGER INGELHEIM INT GMH (DE) 2025-12-18 US disclosed
CN-120192429-A DHODH polypeptide degradation agent and application thereof in preparation of medicine for preventing and/or treating DHODH-mediated diseases 华东理工大学 2025-06-24 CN disclosed
EP-1353924-A1 SYNTHESIS OF TEMOZOLOMIDE AND ANALOGS Schering Corporation (US) 2003-10-22 EP disclosed
US-6458796-B1 METHOD OF TREATING CARDIOVASCULAR DISORDERS, THROMBOEMBOLIC DISORDERS AND ISCHAEMIAS, AND UROGENITAL SYSTEM DISORDERS, COMPRISING ADMINISTERING TO MAMMALS BAYER AKTIENGESELLSCHAFT (DE) 2002-10-01 US disclosed
WO-2002057269-A1 SYNTHESIS OF TEMOZOLOMIDE AND ANALOGS SCHERING CORPORATION (US) 2002-07-25 WO disclosed
US-20020095036-A1 Synthesis of temozolomide and analogs SCHERING CORPORATION 2002-07-18 US disclosed
EP-1214331-A2 2-AZAPURINE COMPOUNDS AND THEIR USE Roche Diagnostics GmbH (DE) 2002-06-19 EP disclosed
WO-2001016149-A2 2-AZAPURINE COMPOUNDS AND THEIR USE ROCHE DIAGNOSTICS GMBH (DE) 2001-03-08 WO disclosed
JP-H11278977-A GAS GENERATOR COMPOSITION DAICEL CHEM IND LTD 1999-10-12 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122690-A1 Method For Increasing Yield Of Staple Food Crop SI, H1-0, H1-3 ALDH1A1 4642/4885PNP 4258/4885PDPK1 2241/4885
US-12527801-B2 Cell activator of animal cell DSG1, DSC1, KRT18 ALDH1A1 2037/4885PNP 4733/4885PDPK1 844/4885
US-20250382344-A1 Soluble GLP1/GIP/NPY2 Receptor Triple Agonists GLP1R, GIPR, NPY1R ALDH1A1 4727/4885PNP 3994/4885PDPK1 1393/4885
US-20260078158-A1 COMPOSITIONS COMPRISING CXCL10-DERIVED PEPTIDES AND METHODS OF USE THEREOF CXCL10, CCL2, CXCR3 ALDH1A1 4811/4885PNP 4078/4885PDPK1 4329/4885
US-20020095036-A1 Synthesis of temozolomide and analogs MGMT, TYMS, MCL1 ALDH1A1 1791/4885PNP 759/4885PDPK1 1231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.